Anti Aging
Conditions
Keywords
Ginseng, Cordyceps, Pomegranate, Red Orange, Grape Seed, Broccoli Seed
Brief summary
Determine the effects of 8 week Investigational Supplement on cellular detoxification and gene expression profiles
Interventions
DIETARY_SUPPLEMENTVitality product AM + Vitality product PM
Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
DIETARY_SUPPLEMENTPlacebo
Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
Sponsors
Aspen Clinical Research
Pharmanex
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
35 Years to 73 Years
Healthy volunteers
Yes
Inclusion criteria
1. Females aged 35-73 years 2. Signed informed consent 3. BMI between 23 and 35 kg/m2 4. A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg 5. BioPhotonic scanner score below 30,000 6. Use of effective method of contraception by females of childbearing \[potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study\]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; or any double barrier method. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal for at least 1 year prior to Visit 1 are not considered to be of childbearing potential. 7. Ability to speak and understand English. 8. Willing to consume one high-fat high carbohydrate meal at the last visit consisting of 1 McDonald's egg Mcmuffin with cheese (no meat), 1 Sausage McMuffin with cheese (no egg), 2 hashbrowns, 1 12 oz Coke Cola or Sprite. 9. Willing to not exercise the morning of your last visit
Exclusion criteria
1. Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue) 2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study. 3. Antihypertensive medication use. 4. Allergies to any ingredients contained in the Investigational Product. 5. Consumption of more than 600 mg of caffeine from all sources per day (equivalent to 24 oz. caffeinated coffee, 96 oz. of soda, 60 oz. of tea, 60 oz. energy drinks , or a combination thereof). 6. Consumption of herbal supplement known to affect energy levels (e.g., ginseng, cordyceps, licorice, Lycium, pomegranate, etc.). 7. Consumption of any of the supplements included in the formulas (Cordyceps sinensis, Panax Ginseng extract, pomegranate extract, red orange complex, grape seed extract or broccoli seed extract). 8. Known iron deficiency anemia. 9. Treatment for insomnia or depression within 30-days prior to the screening visit. 10. Recently started taking medication known to effect energy (e.g., thyroid medication). If taking medication (e.g., thyroid medication), must be stable for at least four months. 11. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit. 12. Planned surgical procedure during the course of the study. 13. Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study. 14. Any laboratory value that the investigator deems clinically significant. 15. Currently participating in a weight loss program or planning to go on a weight loss diet during the course of the study. 16. Allergies to egg or dairy products, Vegetarian or unwilling to consuming sausage.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine effects of investigational supplement on gene expression profiles. | Day 0, Day 28, Day 56 | Gene Expression Panel (microarray PBMCs), Inflammatory Panel, Oxidative stress Markers-including glutathione panel and F2 isoprostane, Anti-oxidant panel, and Lipid Panel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Establish a safety profile of investigational supplement | Day 0, Day 28, Day 56 | Measure number of participants with adverse events. Fasted Safety Labs (chemistry, hematology, Coagulation)compared to baseline. |
| Determine effects of investigational supplement on markers of inflammation | Day 0, Day 28, Day 56 | — |
| Determine changes in scoring on HADS assessment (Hospital Anxiety & Depression Scale) | Day 0, Day 28, Day 56 | Questionnaire: Hospital Anxiety and Depression Scale (HADS) |
| Determine changes in Quality of Life | Day 0, Day 28, Day 56 | SF-36 (Quality of Life Assessment) |
| Determine effects of investigational supplement on composite cognitive index | Day 0, Day 28, Day 56 | — |
| Determine changes to overall health | Day 0, Day 28, Day 56 | Abbreviated Physical Exam |
| Determine changes to biological age scanning (Digital Pulse Wave Analyzer (DPA) | Day 0, Day 28, Day 56 | Digital Pulse Wave Analyzer |
| Determine changes in Biophotonic Scanner Scores | Day 0, Day 28, Day 56 | Measure antioxidants in the palm of the skin. |
| Determine changes in skin advanced glycation endproducts (AGE) levels | Day 0, Day 28, Day 56 | AGE Reader |
| Determine changes in sleep patterns and quality | Day 0, Day 28, Day 56 | Sleep measurement scale. |
Countries
United States
Outcome results
None listed